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Higher milk intake has been associated with a lower stroke risk, but not with risk of coronary 
heart disease (CHD). Residual confounding or reverse causation cannot be excluded. Therefore, 
we estimated the causal association of milk consumption with stroke and CHD risk through 
instrumental variable (IV) and gene-outcome analyses. IV analysis included 29,328 participants 
(4,611 stroke; 9,828 CHD) of the EPIC-CVD (8 European countries) and EPIC-NL case-cohort 
studies. rs4988235, a lactase persistence (LP) single nucleotide polymorphism which enables 
digestion of lactose in adulthood was used as genetic instrument. Intake of milk was first 
regressed on rs4988235 in a linear regression model. Next, associations of genetically predicted 
milk consumption with stroke and CHD were estimated using Prentice-weighted Cox regression. 
Gene-outcome analysis included 777,024 participants (50,804 cases) from MEGASTROKE 
(including EPIC-CVD), UK Biobank and EPIC-NL for stroke, and 483,966 participants (61,612 
cases) from CARDIoGRAM, UK Biobank and EPIC-CVD and EPIC-NL for CHD. In IV 
analyses, each additional LP allele was associated with a higher intake of milk in EPIC-CVD 
(β=13.7 g/day; 95%CI: 8.4-19.1) and EPIC-NL (36.8 g/day; 20.0-53.5). Genetically predicted 
milk intake was not associated with stroke (HR per 25 g/day 1.05; 95%CI: 0.94-1.16) or CHD 
(1.02; 0.96-1.08). In gene-outcome analyses, there was no association of rs4988235 with risk of 
stroke (odds ratios 1.02; 0.99-1.05) or CHD (0.99; 0.95-1.03). Current Mendelian Randomization 
analysis does not provide evidence for a causal inverse relationship between milk consumption 
and stroke or CHD risk.  
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Higher intake of milk has been associated with a modestly lower risk of incident stroke, but not 
coronary heart disease (CHD), in a meta-analysis of observational studies
1
 and more recently in 
EPIC-CVD
2
. However, potential confounding and reverse causation cannot be excluded
3
 and 
therefore any preventive effect of milk consumption in the development of stroke remains 
debatable.   
A Mendelian Randomization (MR) approach
3
 could be used to elucidate the causality of 
this association. An MR study is essentially an instrumental variable (IV) analysis, using one or 
more genetic variants as IV. The assumptions in an MR study are as follows: 1) The genetic 
variant is associated with the determinant of interest. 2) The genetic variant is not associated with 
known or unknown confounders of the determinant-outcome relationship. 3) There is no 
pathway from the genetic variant to disease that does not include the exposure of interest.  
A genetic variant (rs4988235, -13910C>T) near the lactase gene fulfils the first IV 
assumption, as this variant has been associated in European populations with adult lactase 
persistence (LP)
4, 5
, i.e. the continued capacity to produce lactase in the intestinal lumen in 
adulthood. In absence of this enzyme, people cannot break down lactose from dairy products, 
leading to gastro-intestinal symptoms when they consume milk. Alleles conferring LP have been 
associated with a higher intake of milk in most European-ancestry cohorts
6-12
. Furthermore, our 




Previous MR studies in people of European descent reported no association between LP-
associated milk intake and CHD
11, 13
 or with total cardiovascular disease (CVD)
14
. A potential 
causal association between milk consumption and stroke risk has not yet been tested using MR. 
We therefore used rs4988235 in an IV analysis to investigate whether there is a causal 
relationship between LP-predicted milk intake and risk of total and ischaemic stroke and CHD in 
studies of participants of European descent. In addition, we performed gene-outcome analyses 
for the association of rs4988235 with stroke and CHD using data from the EPIC studies, 
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We performed a one-sample MR analysis, further described as IV analysis, in studies for which 
we had access to individual participant phenotype information for habitual intake of milk and 
other foods, on presence of cardiovascular risk factors and stroke and CHD outcomes, as well 
information on rs4988235. We performed gene-outcome analysis using data from several studies 
lacking quantitative data on habitual milk intake. The different studies are further described 
below. 
 
Data for IV analysis   
We used sub-populations of the EPIC study: the EPIC-CVD case-cohort study and the Dutch 
EPIC-NL study.  
 
EPIC-CVD: Among participants with a stored blood sample available, a representative subcohort 
was selected
15, 16
. During follow-up of the EPIC study, incident stroke and CHD cases occurred 
and these participants were added to the EPIC-CVD case-cohort population
17
. We included 
participants with information on intake of milk ((semi-)skimmed or full-fat, regardless of 
fermentation) from region-specific diet questionnaires, the development and validity of which 
were reported previously
15, 18, 19
 and on incident stroke and CHD among those who had data on 
rs4988235. The EPIC-CVD case-cohort study population for this analysis consists of 13,114 
subcohort participants including 397 stroke cases and 521 CHD cases from 8 European 
countries, plus additional cases of stroke (n=3,737) and CHD (n=8,985) (Supplemental methods, 
Figure 1.) Of the 4,134 total stroke cases in the full case-cohort population, 2,746 (66%) were 
identified as ischaemic strokes. In EPIC-CVD, variant rs4988235 was genotyped using the 
Illumina HumanCore Exome Chip array (n=16,685), or genotype dosage was imputed for those 
who were genotyped on the Illumina HumanCoreExome, Illumina OmniExomeExpress, or 
Illumina Quad660 array (n=8,055, impute info~0.42). 
EPIC-NL: In the Dutch EPIC cohort
20
, we selected an additional random subcohort. 
Incident CHD and stroke cases during follow-up of the EPIC-NL study that occurred after the 
follow-up for EPIC-CVD was completed were added to obtain the EPIC-NL case-cohort. Data 
from 3,331 participants with information on milk consumption ((semi-)skimmed or full-fat, 
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used for analysis, including 843 CHD and 567 total stroke cases, of which 410 (72%) were 
identified as ischaemic strokes. We genotyped participants using the Illumina Global Screening 
Assay BeadArray and rs4988235 was imputed at high quality (impute info=0.91). 
The EPIC-CVD study cohort and additional participants from EPIC-NL are described in 
more detail in the Supplemental Methods. The EPIC studies were approved by institutional 
ethical review boards. All participants gave written informed consent prior to inclusion. 
 
Data for gene-outcome analysis 
For the gene-outcome analysis, we included publically available data from various consortia, 
namely UK Biobank, CARDIoGRAM GWAS and MEGASTROKE. We additionally included 
gene-outcome associations from EPIC-CVD and EPIC-NL after exclusion of the population 
overlap with CARDIoGRAM and MEGASTROKE (Supplemental Table 1). A description of 
these cohorts can be found in the supplemental methods. 
 
Data analysis 
In descriptive analyses, we assessed baseline characteristics and dietary intakes in the EPIC-
CVD and EPIC-NL subcohort. We also tested for deviation from Hardy Weinberg Equilibrium 
(HWE)
21
 for rs4988235. 
We investigated IV assumptions
3
, namely whether rs4988235 was reliably associated 
with milk consumption and whether it was associated to cardiometabolic risk factors. For 
continuous variables, we reported a β and 95% confidence interval and for dichotomous 
variables, we reported an odds ratio and 95% confidence interval. We conducted linear 
regression analyses stratified by imputed and hard-call data and pooled the outcomes with fixed-
effects meta-analysis within EPIC-CVD. The models were adjusted for sex, age, the first two 
genetic principal components (PC)
22
, and study centre, assuming an additive effect of 
rs4988235
23
. Additional information can be found in the Supplemental Methods. Dairy non-
consumers were not excluded from analysis since avoidance of dairy could be influenced by 
rs4988235 genotype. None of the aforementioned variables were missing for any of the 
participants.  
Next, we performed a two-stage least squared (2SLS) IV analysis
24
, to investigate 
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separately. LP predicted milk consumption was calculated for each participant by using 
rs4988235, genotyping platform, sex, age, the first two genetic PC and study centre as predictors 
in a linear regression model. LP-predicted milk consumption was scaled to obtain interpretable 
estimates of the hazard ratio for CHD and stroke per 25 g/day increase in milk consumption. We 
fitted a Prentice-weighted Cox proportional hazard model to take the case-cohort design into 
account
25
 with age as underlying time scale and adjusted for sex, the first two genetic PC and 
study centre. We tested the effect of including additional genetic PC in our model, but this 
reduced explained variance (R squared statistic) of the model and did not affect effect estimates. 
Analyses were performed by country in EPIC-CVD. Within countries, the analysis was stratified 
according to hard call versus imputed data for rs4988235 and subsequently pooled across strata 
using fixed effects. Country-specific results from EPIC-CVD and the additional EPIC-NL results 
were then pooled with inverse variance weights in a random effect meta-analysis using restricted 
maximum likelihood estimation. The I squared (I
2
) statistic was used to assess heterogeneity.     
We repeated the aforementioned IV analysis under the assumption of dominance of LP
26
, 
considering only participants with a C/C genotype lactase non persistent. We also performed a 
sensitivity analysis restricting our CHD outcomes to myocardial infarction. Since rs4988235 was 
associated with smoking in EPIC-NL, and smoking is unlikely to mediate an effect of milk 
consumption on CVD, we performed a post-hoc analysis, adjusting our MR estimate for smoking 
status (never versus ever smoker).  
 For the gene-outcome analysis regarding stroke, we used log odds ratios and standard 
errors for the association of rs4988235 with stroke from MEGASTROKE (which already 
included the EPIC-CVD data), and from UK Biobank (adjusted for the first 10 PC). In addition, 
the gene-outcome association between rs4988235 and stroke was investigated in EPIC-NL using 
a Prentice-weighted Cox regression with age as underlying time scale and identical covariates as 
in our IV analysis. The beta and standard errors from MEGASTROKE, UK Biobank and EPIC-
NL were pooled with inverse variance weights in a random effect meta-analysis using restricted 
maximum likelihood estimation to obtain a final estimate for the association between rs4988235 
and risk of stroke.  
For the gene-outcome analysis regarding CHD, we used log odds and standard errors for 
the association of rs4988235 with CHD from CARDIoGRAM and UK Biobank (adjusted for 
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investigated in EPIC-CVD and EPIC-NL using a Prentice-weighted Cox regression with the 
same approach and adjustment for covariates as in our IV analysis. We excluded EPIC-Norfolk 
from the EPIC-CVD analysis since this cohort was included in CARDIoGRAM.  
The beta and standard errors from CARDIOGRAM, UK Biobank, and the combined 
EPIC studies were pooled with inverse variance weights in a random effect meta-analysis using 
restricted maximum likelihood estimation to obtain a relative risk for the association between 
rs4988235 and risk of CHD.  
All analyses and data visualizations were performed in R
27











The EPIC-CVD subcohort participants were on average 52 ± 9 years old and consisted of 60.7% 
women (Supplemental Table 2). Lactase persistence (rs4988235 C/T or T/T) ranged from 30.1% 
in Italy to 95.1% in Denmark. We observed deviation from HWE (at p<0.05) in the total EPIC-
CVD subcohort, and in Denmark and Sweden (Supplemental Table 3). The EPIC-NL subcohort 
had an average age of 51 ± 11 years and consisted of 80.1% women (Supplemental Table 4). 
Lactase persistence occurred at a frequency of 90.3% and genotypes did not deviate from HWE 
(p=0.20). 
Median milk intake was 160 g/day (interquartile range IQR; 39-295) in EPIC-CVD 
(Table 1), ranging from 32 (IQR 2-97) in Germany to 294 (IQR 149-440) in the UK 
(Supplemental Table 5), and 219 g/day (IQR 74-410) in EPIC-NL (Table 2). Dietary intake 
stratified by LP genotype is reported in Supplemental Tables 6 and 7.  
 
Checking IV assumptions  
Each additional T allele was associated with higher milk intake (EPIC-CVD: β 13.7 g/day 
(95%CI 8.4, 19.1); EPIC-NL: β 36.7 g/day (95%CI 19.8, 53.6)), but not with intake of total 
energy or with dairy products other than milk. Each T allele was also associated with lower meat 
intake (EPIC-CVD: β -7.3 g/day (95%CI -12.1, -2.5); EPIC-NL: β -4.4 g/day (95%CI -8.0, -0.9)) 
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In EPIC-CVD (Supplemental Table 8), each T allele was associated to a higher BMI (β 0.15 
kg/m
2
; 95%CI 0.04,0.27) and
 







lower HDL cholesterol (β -0.02 mmol/L; 95%CI -0.03, -0.01) and lower odds of having a history 
of hypercholesterolemia (OR 0.90; 95%CI 0.83, 0.99).  In EPIC-NL (Supplemental Table 9), 
rs4988235 was associated with higher odds of being a never smoker (OR 1.19, 95%CI 1.03-1.37) 
(Supplemental Table 9).  
 
Stroke risk  
In additive IV analysis, genetically predicted milk intake was not associated with risk of total 
stroke (HRper 25 g/day 1.04, 95%CI: 0.94-1.16, I
2
=23%) (Figure 1) or ischaemic stroke (HRper 25 g/day 
1.06, 95%CI: 0.93-1.21, I
2
=22%) (Supplemental Figure 1), although confidence intervals are 
wide. We repeated analysis for total stroke under the assumption of a dominant effect of LP and 
results did not differ (Supplemental Figure 2). Additional adjustment for smoking status in the 
IV analysis of stroke risk in EPIC-NL yielded an HR of 1.15, 95%CI: 1.02-1.29 as compared to 
an HR of 1.14, 95%CI: 1.02-1.27 in original analysis. Gene-outcome analysis did not provide 
evidence for an association between rs4988235 and total stroke risk (OR 1.02, 95%CI: 0.99-1.05, 
I
2
=39%) (Figure 2).  
 
CHD risk  
Genetically predicted milk intake was not associated with risk of CHD, with a pooled HRper 25 
g/day of 1.02 (95%CI: 0.96-1.08, I
2
=0%) (Figure 3). No association with risk of myocardial 
infarction was found either with (HRper 25 g/day 1.00, 95%CI: 0.93-1.07, I
2
=0%)  Results were not 
materially different when assuming a dominant effect of rs4988235 (Supplemental Figure 3). 
Additional adjustment for smoking status in the IV analysis of CHD risk in EPIC-NL yielded an 
HR of 1.00, 95%CI: 0.91-1.11 as compared to an HR of 1.00, 95%CI: 0.91-1.10 in original 
analysis). In gene-outcome analysis, we found no association of rs4988235 with CHD risk, with 
a pooled OR of 0.99 (95%CI: 0.95-1.04, I
2
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In this IV and gene-outcome analysis among people of European descent, we did not find 
evidence for a causal relationship between milk consumption and risk of stroke or CHD.  
Our study has several strengths. First, we used population-based cohorts with extensive 
phenotyping for our IV analysis. This allowed us to investigate the association between LP and 
intake of various (dairy) foods and cardiovascular risk factors, so we can attribute the observed 
association to a well-defined exposure
31
. In addition, we included a large number of participants 
in GWAS and population studies to investigate the association between rs4988235 and risk of 
stroke and CHD. 
There are also limitations to address. First, previous studies have observed an association 
between genetic variation in the lactase region and consumption of total dairy
12, 14
. One of these 
studies showed a 30.3 g/day (95%CI: 21.3-29.3) higher total dairy intake per LP allele, and a 
26.4 g/day (95%CI: 16.7-36.2) higher milk consumption, among 20,028 US participants. In 
EPIC-CVD, each additional LP allele was associated with a 13.6 g/day (95%CI: 8.4-18.8) higher 
milk intake on average, but not with dairy products other than milk (β 1.9 g/day (95%CI: -0.9-
4.7). Milk likely explains most of the association with consumption of total dairy as milk has the 
highest lactose content
32
. However, there may be differences in the association of LP with dairy 
products other than milk between populations and his could affect findings from our gene-




Second, we used dietary questionnaires to estimate milk intake, which are prone to both 
non-differential and differential measurement error. People with clinical symptoms of lactose 
intolerance may be more precise in their recall of dairy consumption, leading to differential 
misclassification. However, we expect misclassification to be non-differential between 
participants with and without later CVD. It is also likely that milk consumption in an individual 
is time-varying, but this is less relevant for an MR study since direction of the population effect 
is expected to remain the same. Also, we observed modest associations of rs4988235 with 
dietary and cardiovascular risk factors in EPIC-NL (e.g. more smoking) and EPIC-CVD (e.g. 
less meat intake), but we consider it unlikely that these modest associations reflect violation of 
the second IV assumption, as discussed in more detail in our previous EPIC-InterAct analysis
10
. 
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(n=8,055, impute info~0.42), so there may be LP genotype misclassification. Also, we observed 
deviation from Hardy-Weinberg equilibrium within EPIC-CVD, which could reflect selection 
bias is genetic population cohorts
21
. However, this deviation can be explained by the widely 
varying allele frequencies for rs4988235 between different European ancestry populations, and 
we have adjusted for potential resulting population stratification via principal components
22
. 
Lastly, outcome definitions for stroke and CHD were somewhat different between the cohorts 
used, but IV sensitivity analyses after restricting to ischemic stroke and myocardial infarction did 
not alter conclusions. Due to aforementioned limitations of our study we cannot exclude a small 
effect of milk consumption on risk of stroke or CHD.  
Despite a modest association found between LP and higher WHR and BMI, which could 
be due to higher energy intake in LP persons
34
, we did not observe an association with 
genetically predicted milk consumption on CHD risk. This lack of association is in line with 
findings from a meta-analysis of prospective cohort studies
1
, a recent EPIC analysis
35
, and a 
previous MR study among a Danish population
11
.  
Regarding total and ischaemic stroke, we did not find support for a protective effect of 
milk consumption in the IV or gene-outcome analysis, although confidence intervals for the IV 
analysis were wide. The biological mechanism of a protective effect of milk intake on stroke risk 
is thought to work via hypertension
36





. We observed no association of lactase persistence with hypertension, or with 
systolic or diastolic blood pressure. In line with our findings, a previous MR study found no 
association between genetically predicted dairy consumption and hypertension
12
. However, a 
recent meta-analysis of 15 prospective cohort studies (4,381,604 participants, 25,377 stroke 
cases) reported an inverse association  (RRper 200 gram/day 0.92 , 95%CI 0.88-0.97) between 
consumption of milk and risk of stroke
1
. This could be because aforementioned association was 
mainly driven by East Asian populations, whereas a null association was observed in western 
populations. It could be hypothesized that people from East Asian descent benefit more from 
milk consumption due to genetic differences with people from European descent, or that 
increasing milk intake on top of a western diet – characterized by a high consumption of refined 
cereals, sugars and vegetable oils, and by consumption of dairy products, fatty meats and salt
39
 – 
does not have a beneficial effect on stroke risk. Another hypothesis could be that the association 
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since the meta-analysis suggests some protective effect of milk intake on stroke risk at any intake 
level
1
. We were unable to test the hypothesis of a non-linear association due to insufficient 
power to perform non-linear MR.  
In conclusion, in IV analyses including 4,611 total stroke and 9,828 CHD cases and gene-
outcome analyses including 50,804 stroke and 61,612 CHD cases, we did not find evidence of a 
causal relation between milk intake and risk of stroke or CHD in European populations. This 
suggests that the inverse association between milk intake and stroke in observational studies may 
be due to confounding. Given the stronger observational evidence for the association between 
milk intake and stroke in East Asian populations with generally lower milk intakes, future 
studies could focus on investigating the relationship between milk intake and stroke in people of 
East Asian descent, or on a potential non-linear association between milk intake and stroke.  
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Table 1. Habitual dietary intake and association between lactase persistence genotype and dietary intake among EPIC-CVD subcohort 
participants. 
  Dietary intake  β* 95% CI    p-value†  I
2
 (%)‡ N 
Total energy (kcal/day)  2051 [1661, 2528]  -2.9 -19.9  14.1   0.74   0.0 13,114 
Milk (g/day) 165 [43, 302]  13.7   8.4  19.1   4.9*10
-7
  69.3 13,114 
Non-milk dairy (g/day) 96 [46, 176]   2.1  -0.8   5.0   0.15   0.0 13,114 
    Milk for coffee and creamers 0 [0, 3]   1.0   0.0   2.0   0.06   0.0 9,048 
    Dairy creams  0 [0, 0]  -0.1  -0.3   0.1   0.32   0.0 6,331 
    Milk based puddings 1 [0, 3]   0.0  -0.1   0.2   0.72   0.0 11,826 
    Curd  0 [0, 11]   0.2  -0.6   1.0   0.59   0.0 9,272 
    Yogurt, thick fermented milk  0 [0, 4]  -0.5  -1.1   0.0   0.06   0.0 9,272 
    Ice cream  25 [0, 97]   0.7  -1.6   3.1   0.54   0.0 13,114 
    Cheese  3 [0, 9]  -0.1  -0.4   0.2   0.49   0.0 13,114 
Vegetables (g/day)  27 [14, 50]  -0.2  -1.0   0.7   0.72  56.0 13,114 
Fruit (g/day)  152 [98, 234]  -2.3  -5.2   0.6   0.12  43.5 13,114 
Meat and meat products (g/day)  186 [100, 306]  -7.3 -12.1  -2.5   3.0*10
-3 
 85.7 13,114 
Fish and shellfish (g/day) 103 [69, 142]  -0.9  -2.4   0.6   0.22  57.5 13,114 
Soft drinks (g/day) 28 [15, 51]   0.3  -0.5   1.1   0.46  64.6 13,114 
Coffee (g/day)  22 [17, 27]  -0.8  -4.8   3.2   0.70  64.8 13,114 
Tea (g/day)  7 [0, 81]   6.2  -1.8  14.1   0.13   0.0 13,114 
Alcohol (g/day)  288 [91, 580]  -5.9 -11.5  -0.4   0.04   0.0 13,114 
Dietary intake data is described as median [p25,p75]. * Beta derived from linear regression model, investigating association between 
additional rs4988235 T alleles with dietary intake, adjusted for sex, age, two genetic PC, and study centre. † p-value of linear 
regression model. ‡ I
2 
for fixed effect meta-analysis of analyses among full EPIC-CVD subcohort stratified by participants with hard 
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Table 2. Habitual dietary intake and association between lactase persistence genotype and dietary intake among 2,025 EPIC-NL 
subcohort participants. 
  Dietary intake  β* 95% CI p-value  
Total energy intake (kcal/day) 
1911 [1625, 
2296] 
-17.4 -52.1 17.3 0.32 
Milk (g/day) 219 [74, 410] 36.7 19.8 53.6 2.2*10
-5 
  Unfermented, unsweetened milk 111 [27, 245] 20.9 7.8 34.1 1.8*10
-3 
  Buttermilk  2 [0, 100] 11.3 1.0 21.7 0.03 
  Sweetened milk  15 [0, 31] 4.4 1.7 7.1 1.6*10
-3 
Non-milk dairy (g/day)  158 [92, 212] 0.6 -8.1 9.2 0.90 
  Curd  7 [2, 12] -0.4 -1.3 0.5 0.39 
  Yogurt  51 [15, 96] -1.8 -8.3 4.7 0.58 
  Cheese 30 [20, 47] -1.1 -3.0 0.7 0.23 
Vegetables (g/day)  133 [104, 169] -2.3 -6.0 1.4 0.22 
Fruit (g/day)  249 [145, 365] -0.1 -11.8 11.6 0.99 
Meat (g/day)  103 [63, 136] -4.4 -8.0 -0.9 0.01 
Fish (g/day) 8 [3, 15] 0.3 -0.4 1.0 0.37 
Beverages †(g/day)  
1463 [1161, 
1833] 
-31.2 -70.1 7.6 0.11 
Alcohol (g/day)  6 [1, 17] 0.1 -1.0 1.1 0.93 
Dietary intake data is described as median [p25,p75]. * Beta and 95% CI derived from linear regression model, adjusting for sex, age, 
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Figure 1. Hazard ratio and 95%CI for each 25 g/day increase in genetically predicted milk intake 
and risk of total stroke in EPIC-CVD countries and in EPIC-NL, assuming an additive effect of 











bridge , on 27 O
ct 2021 at 10:14:13 , subject to the Cam
bridge Core term








Figure 2. Odds ratio or Hazard ratio and 95%CI for each additional rs4998235 lactase 
persistence (T) allele and risk of total stroke in UK Biobank, MEGASTROKE (including EPIC-
CVD data) and EPIC-NL.  
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Figure 3. Hazard ratio and 95%CI for each 25 g/day increase in genetically predicted milk intake 
and risk of CHD in EPIC-CVD countries and in EPIC-NL, assuming an additive effect of 
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Figure 4. Odds ratio or Hazard ratio and 95%CI for each additional rs4998235 lactase 
persistence (T) allele and risk of CHD in UK Biobank, CARDIoGRAM and the EPIC studies 
(EPIC-CVD and EPIC-NL combined). 
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